Telomir Pharmaceuticals (NASDAQ:TELO) & Daiichi Sankyo (OTCMKTS:DSNKY) Head-To-Head Review

Telomir Pharmaceuticals (NASDAQ:TELO) and Daiichi Sankyo (OTCMKTS:DSNKY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Valuation & Earnings

This table compares Telomir Pharmaceuticals and Daiichi Sankyo”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$16.53 million	($0.54)	-3.20
Daiichi Sankyo	$12.39 billion	4.08	$1.95 billion	$1.06	25.14

Daiichi Sankyo has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Daiichi Sankyo, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Telomir Pharmaceuticals and Daiichi Sankyo, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1	0	1	1	2.67
Daiichi Sankyo	0	0	0	1	4.00

Telomir Pharmaceuticals presently has a consensus price target of $15.00, suggesting a potential upside of 767.05%. Given Telomir Pharmaceuticals’ higher possible upside, research analysts plainly believe Telomir Pharmaceuticals is more favorable than Daiichi Sankyo.

Profitability

This table compares Telomir Pharmaceuticals and Daiichi Sankyo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-4,595.08%	-1,750.91%
Daiichi Sankyo	15.40%	18.39%	8.57%

Summary

Daiichi Sankyo beats Telomir Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.